Chronic Lymphocytic Leukemia

CLL is a rare indication for HCT/Cellular Therapy since it usually follows an indolent course. Allogeneic HCT is considered as standard of care in eligible high-risk patients who have failed at least two classes of modern pathway inhibitor-based therapy, and in select patients with CLL transformed in to an aggressive B-cell lymphoma (Richter transformation). Except for Richter transformation, there is no role for autologous HCT in CLL. In the absence of a labeled indication, CAR T-cells should not be used outside of clinical trials.